> G. Steven Burrill is touting the (relative) success of his Burrill Biotech Select Index compared to the swooning Nasdaq and sounds quite bullish about the impact of M&As in biotech [1]. Report [2]
> The FDA has approved an NDA from Forest Laboratories and Mylan for nebivolol, or Bystolic, for hypertension. Forest is planning to launch in January, saying that the FDA's concerns about a backup facility can be dealt with quickly. Release [3]
> Apparently, GlaxoSmithKline's dynamic duo is worth $4.1 million each. The two execs passed over for the CEO job--Chris Viehbacher (photo [4]) and David Stout (photo [5])--will each get a retention package worth that much if shareholders approve. Report [6]
> Prepping for his January inauguration, CEO-in-waiting Bernard Poussot (photo [7]) has tapped a handful of current Wyeth-ites to fill top positions in the company. Report [8]
> Henry Waxman, chairman of the House Committee on Oversight and Government Reform, is protesting an off-label marketing "loophole." Report [9]
> Chutes & Ladders: Arrowhead Research has named Christopher Anzalone as CEO and is in the process of buying the private equity group he founded. Report [10]
> AEterna Zentaris has closed on the $3.2 million sale of Echelon Biosciences to Frontier Scientific. Release [11]
And Finally… Intelligent software may be the key to developing the perfect artificial hand. Release [12]
Links:
[1] http://www.fiercebiotech.com/tags/acquired
[2] http://www.fiercebiotech.com/story/burrill-bullish-m/2007-12-03
[3] http://www.fiercebiotech.com/press-releases/fda-issues-approvable-letter-nebivolol-treatment-hypertension
[4] http://www.fiercebiotech.com/pages/gsks-chris-viehbacher
[5] http://www.fiercebiotech.com/pages/gsks-david-stout
[6] http://www.fiercepharma.com/story/gsk-runners-get-4m-board-seat/2007-12-03
[7] http://www.fiercebiotech.com/pages/wyeth-ceo-bernard-poussot?utm_medium=nl&utm_source=internal
[8] http://www.fiercepharma.com/story/wyeth-ceo-taps-new-management-team/2007-12-03
[9] http://www.fiercepharma.com/story/rep-decries-label-marketing-loophole/2007-12-03
[10] http://biz.yahoo.com/ap/071203/arrowhead_research_ceo.html?.v=1
[11] http://www.fiercebiotech.com/press-releases/aeterna-zentaris-sells-echelon-biosciences-frontier-scientific
[12] http://www.fiercebiotech.com/press-releases/press-release-intelligent-software-helps-build-perfect-robotic-hand